Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62019TA0643

Case T-643/19: Judgment of the General Court of 18 November 2020 — Dermavita v EUIPO — Allergan Holdings France (JUVEDERM ULTRA) (EU trade mark — Revocation proceedings — EU word mark JUVEDERM ULTRA — Genuine use of the mark — Use in connection with the goods in respect of which the mark was registered — Use in the form in which the mark was registered — Use with the proprietor’s consent — Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))

IO C 9, 11.1.2021, pp. 16–17 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

11.1.2021   

EN

Official Journal of the European Union

C 9/16


Judgment of the General Court of 18 November 2020 — Dermavita v EUIPO — Allergan Holdings France (JUVEDERM ULTRA)

(Case T-643/19) (1)

(EU trade mark - Revocation proceedings - EU word mark JUVEDERM ULTRA - Genuine use of the mark - Use in connection with the goods in respect of which the mark was registered - Use in the form in which the mark was registered - Use with the proprietor’s consent - Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))

(2021/C 9/24)

Language of the case: English

Parties

Applicant: Dermavita Co. Ltd (Beirut, Lebanon) (represented by: D. Todorov, lawyer)

Defendant: European Union Intellectual Property Office (represented by: J. Crespo Carrillo, V.J. Ruzek, and K. Zajfert, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Allergan Holdings France (Courbevoie, France) (represented by: J. Day, Solicitor, and T. de Haan, lawyer)

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France.

Operative part of the judgment

The Court:

1.

Dismisses the action;

2.

Orders Dermavita Co. Ltd to bear its own costs and to pay those incurred by the European Union Intellectual Property Office (EUIPO);

3.

Orders Allergan Holdings France to bear its own costs.


(1)  OJ C 383, 11.11.2019.


Top